Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy
Osama M. Soltan, Mai E. Shoman, Salah A. Abdel‐Aziz, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113768-113768
Closed Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
Mohammed A. S. Abourehab, Alaa M. Alqahtani, Bahaa G. M. Youssif, et al.
Molecules (2021) Vol. 26, Iss. 21, pp. 6677-6677
Open Access | Times Cited: 125
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
Ali Doostmohammadi, Hossein Jooya, Kimia Ghorbanian, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 27
Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers
Zhi Xu, Yafei Zhuang, Qingtai Chen
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115495-115495
Closed Access | Times Cited: 25
Recent updates on thienopyrimidine derivatives as anticancer agents
Menna Tallah M. Sayed, Rasha A. Hassan, Peter A. Halim, et al.
Medicinal Chemistry Research (2023) Vol. 32, Iss. 4, pp. 659-681
Open Access | Times Cited: 23
Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors
Changqun Liu, Yuening Cao, Yi Y. Zuo, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 10
Catalyst-free late-stage functionalization to assemble α-acyloxyenamide electrophiles for selectively profiling conserved lysine residues
Yuanyuan Zhao, Duan Kang, Youlong Fan, et al.
Communications Chemistry (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 8
Antineoplastic indole-containing compounds with potential VEGFR inhibitory properties
Dalia R. Aboshouk, Mohamed A. Youssef, Mohamed S. Bekheit, et al.
RSC Advances (2024) Vol. 14, Iss. 9, pp. 5690-5728
Open Access | Times Cited: 8
Design, synthesis and molecular modeling of novel D-ring substituted steroidal 4,5-dihydropyrazole thiazolinone derivatives as anti-inflammatory agents by inhibition of COX-2/iNOS production and down-regulation of NF-κB/MAPKs in LPS-induced RAW264.7 macrophage cells
Xiaorui Cai, Jianfeng Cai, Ling Fang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116460-116460
Closed Access | Times Cited: 7
Preparation And Identification of Some New Unsaturated Ketone Derivatives of Clotrimazole
Ali Hussein Shanwa, Raheem Jameel Mohasein
Research Square (Research Square) (2025)
Closed Access
Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors
Islam H. Ali, Heba T. Abdel‐Mohsen, Marwa M. Mounier, et al.
Bioorganic Chemistry (2022) Vol. 126, pp. 105883-105883
Closed Access | Times Cited: 33
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
Weixin Zhang, Jiao Huang, Xin-Yi Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115673-115673
Closed Access | Times Cited: 20
Multitarget antibacterial drugs: An effective strategy to combat bacterial resistance
Jin Feng, Youle Zheng, Wanqing Ma, et al.
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108550-108550
Closed Access | Times Cited: 19
Novel VEGFR‐2 Kinase Inhibitors as Anticancer Agents: A Review Focusing on SAR and Molecular Docking Studies (2016–2021)
S. Vishakha, Kumari Kajal, Sitanshu Mondal, et al.
Chemistry & Biodiversity (2023) Vol. 20, Iss. 2
Closed Access | Times Cited: 17
Coumarin derivatives with potential anticancer and antibacterial activity: Design, synthesis, VEGFR‐2 and DNA gyrase inhibition, and in silico studies
Soha H. Emam, Rasha A. Hassan, Eman O. Osman, et al.
Drug Development Research (2023) Vol. 84, Iss. 3, pp. 475-499
Closed Access | Times Cited: 17
Novel 7-Chloro-4-aminoquinoline-benzimidazole Hybrids as Inhibitors of Cancer Cells Growth: Synthesis, Antiproliferative Activity, in Silico ADME Predictions, and Docking
Luka Krstulović, Marijana Jukić, Vesna Rastija, et al.
Molecules (2023) Vol. 28, Iss. 2, pp. 540-540
Open Access | Times Cited: 15
Design and synthesis of antiproliferative 2-oxoindolin-3-ylidenes incorporating urea function with potential VEGFR-2 inhibitory properties
Dalia R. Aboshouk, Mohamed A. Youssef, Siva S. Panda, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Discovery of new benzothiazole-1,2,3-triazole hybrid-based hydrazone/thiosemicarbazone derivatives as potent EGFR inhibitors with cytotoxicity against cancer
Ateyatallah Aljuhani, Mohamed S. Nafie, Nader R. Albujuq, et al.
RSC Advances (2025) Vol. 15, Iss. 5, pp. 3570-3591
Open Access
Design, Synthesis, Docking Studies, and Investigation of Dual EGFR/VEGFR‐2 Inhibitory Potentials of New Pyrazole and Pyrazolopyridine Derivatives
Shimaa M. Alhamaky, Nadia A. Khalil, Amr K.A. Bass, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
Dandan Yuan, Yali Gao, Lin Xia, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2025) Vol. 40, Iss. 1
Open Access
Design, Synthesis, and In Silico Insights of new 4‐Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines
Gabriele La Monica, Alessia Bono, Federica Alamia, et al.
ChemistryOpen (2025)
Open Access
Synthesis of novel quinoline-thiazolobenzimidazolone hybrids as anticancer agents through caspase-dependent apoptosis
Houria Bouria, Hayette Alliouche, Mohamed Imed Chouiter, et al.
Future Medicinal Chemistry (2025), pp. 1-13
Closed Access
Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors
Christine Tran, Abdallah Hamzé
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 341-341
Open Access
Design, synthesis, in silico studies and antiproliferative evaluation of some novel hybrids of pyrimidine-morpholine
Elaheh Ataollahi, Leila Emami, Al-Anood M. Al-Dies, et al.
Frontiers in Chemistry (2025) Vol. 13
Open Access
Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma
Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 5
Closed Access | Times Cited: 4
Research progress of DDR1 inhibitors in the treatment of multiple human diseases
Mengying Liu, Jifa Zhang, Xiaoxue Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116291-116291
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top